
Oculis Holding AG Investor Relations Material
Latest events

R&D Day 2025
Oculis Holding AG
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Oculis Holding AG
Access all reports
Oculis Holding AG is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company's product pipeline includes several advanced-stage candidates designed to address significant unmet needs in ophthalmology. Notable among these are OCS-01, a topical eye drop for diabetic macular edema and post-cataract surgery inflammation, OCS-02, a topical biologic targeting dry eye disease and uveitis, and OCS-05, aimed at neuro-ophthalmic conditions such as acute optic neuritis and glaucoma. The company is headquartered in Zug, Switzerland, and its shares are listed on the Nasdaq.
Key slides for Oculis Holding AG


Corporate Presentation
Oculis Holding AG


Corporate Presentation
Oculis Holding AG
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
OCS
Country
🇺🇸 United States